Contents

Summary of decisions effective 1 June 2017 .................................................. 3
Section H changes to Part II ............................................................................ 4
Index ........................................................................................................... 12
Summary of decisions
EFFECTIVE 1 JUNE 2017

• Alfacalcidol (One-Alpha) cap 0.25 mcg and 1 mcg – addition of HSS
• Alfacalcidol (One-Alpha) oral drops 2 mcg per ml – new listing and addition of HSS
• Amoxicillin with clavulanic acid (Curam) granules for oral liq 50 mg with clavulanic acid 12.5 mg per ml – brand change and addition of HSS
• Amoxicillin with clavulanic acid (Augmentin) granules for oral liq 50 mg with clavulanic acid 12.5 mg per ml – to be delisted 1 August 2017
• Aminolevulinic acid hydrochloride (Gliolan) powder for oral soln, 30 mg per ml, 1.5 g vial – new listing
• Celecoxib (Celecoxib Pfizer) cap 100 mg and 200 mg – new listing and addition of HSS
• Celecoxib cap 400 mg – to be delisted 1 August 2017
• Dimethicone (healthE Dimethicone 4% Lotion) lotn 4%, 200 ml – amended therapeutic subgroup
• Influenza vaccine (Influvac) inj 45 mcg in 0.5 ml syringe – HSS removed
• Morphine tartrate (Hospira) inj 80 mg per ml, 5 ml ampoule – to be delisted 1 August 2017
• Nifedipine (Adalat 10) tab long-acting 10 mg – new listing and addition of HSS
• Nystatin (Nilstat) vaginal crm 100,000 u per 5 g with applicator(s), 75 g – new listing and addition of HSS
• Pegylated interferon alfa-2a (Pegasys RBV Combination Pack) inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) – to be delisted 1 August 2017
• Peptide-based enteral feed 1.5 kcal/ml (Vital) liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle – amended chemical name
• Pyridoxine hydrochloride inj 100 mg per ml, 30 ml vial – new listing
• Sulphadiazine silver (Flamazine) crm 1%, 50 g – price decrease and addition of HSS
• Temozolomide (Orion Temozolomide) cap 5 mg, 20 mg, 100 mg and 250 mg – amended restriction
• Testosterone (Androderm) patch 5 mg per day – new listing
Section H changes to Part II
Effective 1 June 2017

ALIMENTARY TRACT AND METABOLISM

27 ALFACALCIDOL (addition of HSS)
   Cap 0.25 mcg – 1% DV Aug-17 to 2020 ........................................26.32 100 One-Alpha
   Cap 1 mcg – 1% DV Aug-17 to 2020 ............................................87.98 100 One-Alpha

27 ALFACALCIDOL (new listing)
   Oral drops 2 mcg per ml – 1% DV Aug-17 to 2020 .....................60.68 20 ml One-Alpha

27 PYRIDOXINE HYDROCHLORIDE (new listing)
   Inj 100 mg per ml, 30 ml vial

CARDIOVASCULAR SYSTEM

46 NIFEDIPINE (new listing and addition of HSS)
   Tab long-acting 10 mg – 1% DV Aug-17 to 2020 .............................10.63 60 Adalat 10

DERMATOLOGICALS

54 SULPHADIAZINE SILVER († price and addition of HSS)
   Crm 1% – 1% DV Aug-17 to 2020 ................................................10.80 50 g Flamazine

55 Antiparasitics Barrier Creams (amended Therapeutic subgroup)
   DIMETHICONDE
   Lotn 4% – 1% DV Jul-17 to 2019 ........................................4.98 200 ml healthE Dimethicone 4% Lotion

GENITO-URINARY SYSTEM

60 NYSTATIN (new listing and addition of HSS)
   Vaginal crm 100,000 u per 5 g with applicator(s)
   – 1% DV Aug-17 to 2020 .........................................................4.45 75 g Nilstat

HORMONE PREPARATIONS

65 TESTOSTERONE (new listing)
   Patch 5 mg per day .................................................................80.00 30 Androderm

INFECTIONS

78 AMOXICILLIN WITH CLAVULANIC ACID (brand change)
   Grans for oral liq 50 mg with clavulanic acid
   12.5 mg per ml – 1% DV Aug-17 to 2019 .................................2.20 100 ml Curam
   Note – Augmentin grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml to be delisted from
   1 August 2017.
97 PEGYLATED INTERFERON ALFA-2A (delisting)
   ➔ Inj 180 mcg prefilled syringe (4) with ribavirin tab
   200 mg (112) .................................1,159.84 1 Pegasys RBV Combination Pack
   Note – Pegasys RBV Combination Pack inj 180 mcg prefilled syringe (4) with ribavirin tab 200 ng (112) to be delisted from 1 August 2017.

MUSCULOSKELETAL SYSTEM

107 CELECOXIB (new listing and addition of HSS)
   ➔ Cap 100 mg – 1% DV Aug-17 to 2020.................................3.63 60 Celecoxib Pfizer
   ➔ Cap 200 mg – 1% DV Aug-17 to 2020.................................2.30 30 Celecoxib Pfizer
   Note – The DV limit of 1% applies to the celecoxib chemical rather than each individual line item.
   Note – Celecoxib cap 400 mg to be delisted from 1 August 2017.

NERVOUS SYSTEM

115 MORPHINE TARTRATE (delisting)
   Inj 80 mg per ml, 5 ml ampoule ........................................107.67 5 Hospira
   Note – Hospira inj 80 mg per ml, 5 ml ampoule to be delisted from 1 August 2017.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

140 TEMOZOLOMIDE (amended restriction)
   ➔ Cap 5 mg – 1% DV Feb-17 to 2019.................................10.20 5 Orion Temozolomide
   ➔ Cap 20 mg – 1% DV Feb-17 to 2019.................................18.30 5 Orion Temozolomide
   ➔ Cap 100 mg – 1% DV Feb-17 to 2019.................................40.20 5 Orion Temozolomide
   ➔ Cap 250 mg – 1% DV Feb-17 to 2019.................................96.80 5 Orion Temozolomide

   Restricted
   Initiation — High grade gliomas
   Re-assessment required after 12 months
   All of the following:
   1 Either:
      1.1 Patient has newly diagnosed glioblastoma multiforme; or
      1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
   2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
   3 Following concomitant treatment temozolomide is to be used for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m2 per day.

   Initiation — Neuroendocrine tumours
   Re-assessment required after 9 months
   All of the following:
   1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*; and
   2 Temozolomide is to be given in combination with capecitabine; and
   3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m2 per day; and
   4 Temozolomide to be discontinued at disease progression.

   Continuation — High grade gliomas
   Re-assessment required after 12 months
   Either:
   1 Both:

continued...
Changes to Section H Part II – effective 1 June 2017 (continued)

1.1 Patient has glioblastoma multiforme; and
1.2 The treatment remains appropriate and the patient is benefitting from treatment; or
2 All of the following:
2.1 Patient has anaplastic astrocytoma*; and
2.2 The treatment remains appropriate and the patient is benefitting from treatment; and
2.3 Adjuvant temozolomide is to be used for a maximum of 24 months.

Continuation — Neuroendocrine tumours
Re-assessment required after 6 months
Both:
1 No evidence of disease progression; and
2 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indication marked with a * is an Unapproved Indication. Temozolomide is not funded for the treatment of relapsed glioblastoma multiforme high grade glioma.

147 AMINOLEVULINIC ACID HYDROCHLORIDE (new listing)
Powder for oral soln, 30 mg per ml, 1.5 g vial ..........................4,400.00 1 Gliolan
44,000.00 10 Gliolan

Restricted
Initiation – high grade malignant glioma
All of the following:
1 Patient has newly diagnosed, untreated, glioblastoma multiforme; and
2 Treatment to be used as adjuvant to fluorescence-guided resection; and
3 Patient’s tumour is amenable to complete resection.

SPECIAL FOODS

216 PEPTIDE-BASED ORAL ENTERAL FEED 1.5 KCAL/ML (amended chemical name)
Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per
100 ml, bottle .................................................................18.06 1,000 ml Vital

VACCINES

229 INFLUENZA VACCINE (HSS expired)
Inj 45 mcg in 0.5 ml syringe
– 0% DV Feb-17 to 31 Dec 2019 31 May 2017 ........................90.00 10 Influvac

(Brand) indicates a brand example only. It is not a contracted product.
Changes to Section H Part II – effective 1 May 2017

DERMATOLOGICALS

<table>
<thead>
<tr>
<th>No.</th>
<th>Product Description</th>
<th>Details</th>
<th>Price</th>
<th>Brand or Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td>DIMETHICONE (new listing and addition of HSS)</td>
<td>Lotn 4% - 1% <strong>DV Jul-17 to 2019</strong></td>
<td>4.98</td>
<td>healthE Dimethicone 4% Lotion</td>
</tr>
<tr>
<td>58</td>
<td>CALCIPOTRIOL (addition of HSS)</td>
<td>Oint 50 mcg per g – 1% <strong>DV Jul-17 to 2020</strong></td>
<td>45.00</td>
<td>Daivonex</td>
</tr>
</tbody>
</table>

HORMONE PREPARATIONS

<table>
<thead>
<tr>
<th>No.</th>
<th>Product Description</th>
<th>Details</th>
<th>Price</th>
<th>Brand or Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>66</td>
<td>DEXAMETHASONE PHOSPHATE (new pack size)</td>
<td>Inj 4 mg per ml, 2 ml ampoule – 1% <strong>DV Jul-16 to 2019</strong></td>
<td>25.18</td>
<td>Max Health</td>
</tr>
</tbody>
</table>

INFECTIONS

<table>
<thead>
<tr>
<th>No.</th>
<th>Product Description</th>
<th>Details</th>
<th>Price</th>
<th>Brand or Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>78</td>
<td>PIPERACILLIN WITH TAZOBACTAM (new listing)</td>
<td>Inj 4 g with tazobactam 0.5 g vial</td>
<td>15.50</td>
<td>Tazocin EF</td>
</tr>
<tr>
<td>86</td>
<td>METRONIDAZOLE (new listing)</td>
<td>Inj 5 mg per ml, 100 ml bottle</td>
<td>1.39</td>
<td>AFT</td>
</tr>
</tbody>
</table>

NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>No.</th>
<th>Product Description</th>
<th>Details</th>
<th>Price</th>
<th>Brand or Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>128</td>
<td>FLUPHENAZINE DECANOATE – Restricted: For continuation only (delisting)</td>
<td>Inj 12.5 mg per 0.5 ml ampoule</td>
<td>17.60</td>
<td>Modecate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 25 mg per ml, 1 ml ampoule</td>
<td>27.90</td>
<td>Modecate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 25 mg per ml, 2 ml ampoule</td>
<td>e.g. Modecate</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 100 mg per ml, 1 ml ampoule</td>
<td>154.50</td>
<td>Modecate</td>
</tr>
<tr>
<td></td>
<td>Note – Modecate inj 12.5 mg per 0.5 ml, inj 25 mg per ml, 1 ml and 2 ml, and 100 mg per ml, 1 ml ampoules to be delisted from 1 December 2017.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>No.</th>
<th>Product Description</th>
<th>Details</th>
<th>Price</th>
<th>Brand or Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>184</td>
<td>AZATHIOPRINE (brand change)</td>
<td>Tab 25 mg – 1% <strong>DV Jul-17 to 2019</strong></td>
<td>9.66</td>
<td>Imuran</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tab 50 mg – 1% <strong>DV Jul-17 to 2019</strong></td>
<td>10.58</td>
<td>Imuran</td>
</tr>
<tr>
<td></td>
<td>Note – Azamun tab 25 mg and 50 mg to be delisted from 1 July 2017.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>No.</th>
<th>Product Description</th>
<th>Details</th>
<th>Price</th>
<th>Brand or Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>191</td>
<td>SODIUM CROMOGLYCATE (delisting)</td>
<td>Powder for inhalation 20 mg per dose</td>
<td>Note – Sodium cromoglycate powder for inhalation 20 mg per dose to be delisted from 1 June 2017.</td>
<td></td>
</tr>
</tbody>
</table>
Changes to Section H Part II – effective 1 May 2017 (continued)

VACCINES

229  INFLUENZA VACCINE (Restriction amended (affected criterion only shown))

⇒ Inj 45 mcg in 0.5 ml syringe

− 0% DV Feb-17 to 31 Dec 2019 .............................................. 90.00 10  Influvac

Restricted

Initiation — Other conditions

Any of the following Either:

1 Any of the following:
   1.1 Diabetes; or
   1.2 chronic renal disease; or
   1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
   1.4 Autoimmune disease; or
   1.5 Immune suppression or immune deficiency; or
   1.6 HIV; or
   1.7 Transplant recipient; or
   1.8 Neuromuscular and CNS diseases/ disorders; or
   1.9 Haemoglobinopathies; or
   1.10 Is a child on long term aspirin; or
   1.11 Has a cochlear implant; or
   1.12 Errors of metabolism at risk of major metabolic decompensation; or
   1.13 Pre and post splenectomy; or
   1.14 Down syndrome; or
   1.15 Is pregnant; or
   1.16 Is a child aged four and under who has been hospitalised for respiratory illness or has a history of
   significant respiratory illness; or

2 Patients who are compulsorily detained long-term in a forensic unit within a DHB hospital; or

3 People under 18 years of age living within the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board).
Changes to Section H Part II – effective 1 April 2017

**BLOOD AND BLOOD FORMING ORGANS**

40 SODIUM CHLORIDE (new listing)
   Inj 0.9%, 20 ml ampoule........................................5.00  20  Multichem

40 SODIUM CHLORIDE (HSS suspended)
   Inj 0.9%, 20 ml ampoule – 1% DV Mar-17 to 2019
   31 Mar 2017......................................................7.50  30  InterPharma

40 WATER (new listing)
   Inj 20 ml ampoule........................................5.00  20  Multichem

40 WATER (HSS suspended)
   Inj 20 ml ampoule – 1% DV Mar-17 to 2019
   31 Mar 2017........................................7.50  30  Interpharma

**CARDIOVASCULAR SYSTEM**

44 AMIODARONE HYDROCHLORIDE (brand change)
   Inj 50 mg per ml, 3 ml ampoule – 1% DV Jun-17 to 2019............9.98  5  Lodi
   Note – Cordarone-X inj 50 mg per ml, 3 ml ampule to be delisted from 1 June 2017.

**GENITO-URINARY SYSTEM**

61 LEVONORGESTREL (1 price and addition of HSS)
   Tab 1.5 mg – 1% DV Jun-17 to 2019.................................4.95  1  Postinor-1

**HORMONE PREPARATIONS**

67 PREDNISONE (addition of HSS)
   Tab 1 mg – 1% DV Jun-17 to 2020...............................10.68  500  Apo-Prednisone
   Tab 2.5 mg – 1% DV Jun-17 to 2020..............................12.09  500  Apo-Prednisone
   Tab 5 mg – 1% DV Jun-17 to 2020.................................11.09  500  Apo-Prednisone
   Tab 20 mg – 1% DV Jun-17 to 2020..............................29.03  500  Apo-Prednisone

68 CLOMIFENE CITRATE (chemical name change)
   Tab 50 mg............................................................29.84  10  Mylan Clomiphen
   Serophene

**INFECTIONS**

81 FUSIDIC ACID (addition of HSS)
   ➤ Tab 250 mg – 1% DV Jun-17 to 2020.............................34.50  12  Fucidin

90 DARUNAVIR (1 price and addition of HSS)
   ➤ Tab 400 mg – 1% DV Jun-17 to 2020............................335.00  60  Prezista
   ➤ Tab 600 mg – 1% DV Jun-17 to 2020............................476.00  60  Prezista

Products with Hospital Supply Status (HSS) are in **bold**.
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
Changes to Section H Part II – effective 1 April 2017 (continued)

MUSCULOSKELETAL SYSTEM

99 AURANOIN - Restricted: for continuation only (restriction added and delisting)
   Tab 3 mg
   Note – Auranofin tab 3 mg to be delisted from 1 September 2017.

99 LEFLUNOMIDE (brand change)
   Tab 10 mg – 1% DV Jun-17 to 2020............................. 2.90 30 Apo-Leflunomide
   Tab 20 mg – 1% DV Jun-17 to 2020............................. 2.90 30 Apo-Leflunomide
   Note – Arava tab 10 mg and 20 mg to be delisted from 1 June 2017.

108 NAPROXEN (amended pack size)
   Tab long-acting 750 mg – 1% DV Jun-15 to 2018......... 5.60 28 Naprosyn SR 750
   Tab long-acting 1 g – 1% DV Jun-15 to 2018............. 6.53 28 Naprosyn SR 1000
   Note – Naproxen tab 750 mg and 1 g pack size change from 90 pack bottle to 28 blister pack. The 90 tablet packs will be delisted at a later date.

NERVOUS SYSTEM

109 BENZATROPINE (chemical name change)
   Tab 2 mg ............................................................... 7.99 60 Benztrap
   Inj 1 mg per ml, 2 ml ampoule ................................. 95.00 5 Cogentin

117 VENLAFAXINE (brand change)
   Cap 37.5 mg – 1% DV Jun-17 to 2020..................... 6.38 84 Enlafax XR
   Cap 75 mg – 1% DV Jun-17 to 2020....................... 8.11 84 Enlafax XR
   Cap 150 mg – 1% DV Jun-17 to 2020...................... 11.16 84 Enlafax XR
   Note – Arrow-Venlafaxine XR tab modified release 37.5 mg, 75 mg, 150 mg and 225 mg, and Efexor XR cap modified release 37.5 mg, 75 mg and 150 mg to be delisted from 1 June 2017.

123 APREPITANT (new listing)
    Cap 40 mg ........................................................... 71.43 5 Emend

123 SUMATRIPTAN (brand change)
   Tab 50 mg – 1% DV Jun-17 to 2019......................... 24.44 100 Apo-Sumatriptan
   Tab 100 mg – 1% DV Jun-17 to 2019...................... 46.23 100 Apo-Sumatriptan
   Note – Arrow-Sumatriptan tab 50 mg and 100 mg to be delisted from 1 June 2017.

124 GRANISETRON (delisting)
   Tab 1 mg – 1% DV Jan-15 to 2017......................... 5.98 50 Granirex
   Note – Granirex tab 1 mg to be delisted from 1 October 2017.

134 BUPROPION HYDROCHLORIDE (addition of HSS)
   Tab modified-release 150 mg – 1% DV Jun-17 to 2020..... 11.00 30 Zyban

 Restriction (Brand) indicates a brand example only. It is not a contracted product.
Changes to Section H Part II – effective 1 April 2017 (continued)

**ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS**

142 ERLOTINIB (amended restriction – amended criteria shown only)

- Tab 100 mg…………………………………………………………………………764.00 30 Tarceva
- Tab 150 mg…………………………………………………………………………1,146.00 30 Tarceva

Restricted

Initiation

*Re-assessment required after 4 months*

All of the following:

1 Patient has locally advanced or metastatic, unresectable, non-squamous Non-Small Cell Lung Cancer (NSCLC); and

2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and

3 Either Any of the following:
   - 3.1 Patient is treatment naive; or
   - 3.2 Both:
     - 3.2.1 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and
     - 3.2.2 Patient has not received prior treatment with gefitinib; or
   - 3.3 Both:
     - 3.3.1 The patient has discontinued gefitinib within 12 weeks of starting treatment due to intolerance; and
     - 3.3.2 The cancer did not progress while on gefitinib; and

4 Erlotinib is to be given for a maximum of 3 months.

**SPECIAL FOODS**

211 PROTEIN SUPPLEMENT (delisting)

- Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can

  e.g. Promod

Note – Promod powder to be delisted from 1 April 2017.

213 AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) (delisting)

- Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can

  e.g. MSUD Maxamaid

Note – MSUD Maxamaid to be delisted from 1 May 2017.
### Index
Pharmaceuticals and brands

<table>
<thead>
<tr>
<th>Letter</th>
<th>Pharmaceutical/Brand</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Adalat 10</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Alfalcaldol</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Amino acid formula (without isoleucine, leucine and valine).</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>Aminolevulinic acid hydrochloride</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Amiodarone hydrochloride</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Amoxicillin with clavulanic acid</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Androderm</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Apo-Leflunomide</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Apo-Prednisone</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Apo-Sumatriptan</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Aprepitant</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Auranofin</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Azathioprine</td>
<td>7</td>
</tr>
<tr>
<td>B</td>
<td>Benztropine mesylate</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Benztrop</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Benztropine mesylate</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Bupropion hydrochloride</td>
<td>10</td>
</tr>
<tr>
<td>C</td>
<td>Calcipotriol</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Celecoxib</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Celecoxib Pfizer</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Clomifene citrate</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Clomiphene citrate</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Cogentin</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Curam</td>
<td>4</td>
</tr>
<tr>
<td>D</td>
<td>Daivonex</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Darunavir</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Dexamethasone phosphate</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Dimethicone phosphate</td>
<td>4, 7</td>
</tr>
<tr>
<td>E</td>
<td>Emend</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Enlafax XR</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Erlotinib</td>
<td>11</td>
</tr>
<tr>
<td>F</td>
<td>Flamazine</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Fluphenazine decanoate</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Fucidin</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Fusidic acid</td>
<td>9</td>
</tr>
<tr>
<td>G</td>
<td>Gliolan</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Granirex</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Granisetron</td>
<td>10</td>
</tr>
<tr>
<td>H</td>
<td>healthE Dimethicone 4% Lotion</td>
<td>4, 7</td>
</tr>
<tr>
<td>I</td>
<td>Imuran</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Influenza vaccine</td>
<td>6, 8</td>
</tr>
<tr>
<td>L</td>
<td>Leflunomide</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Levonorgestrel</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Lodi</td>
<td>9</td>
</tr>
<tr>
<td>M</td>
<td>Metronidazole</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Modecate</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Morphine tartrate</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>MSUD Maxamaid</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>Mylan Clomiphen</td>
<td>9</td>
</tr>
<tr>
<td>N</td>
<td>Naprosyn SR 750</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Naprosyn SR 1000</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Naproxen</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Nifedipine</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Nilstat</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Nystatin</td>
<td>4</td>
</tr>
<tr>
<td>O</td>
<td>One-Alpha</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Orion Temozolomide</td>
<td>5</td>
</tr>
<tr>
<td>P</td>
<td>Pegasys RBV Combination Pack</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Pegylated interferon alfa-2a</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Peptide-based enteral feed 1.5 Kcal/ml</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Piperacillin with tazobactam</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Postinor-1</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Prednisone</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Prezista</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Promod</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>Protein supplement</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>Pyridoxine hydrochloride</td>
<td>4</td>
</tr>
<tr>
<td>S</td>
<td>Serophene</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Sodium chloride</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Sodium cromoglycate</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Sulphadiazine silver</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Sumatriptan</td>
<td>10</td>
</tr>
<tr>
<td>T</td>
<td>Tarceva</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>Tazocin EF</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Temozolomide</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Testosterone</td>
<td>4</td>
</tr>
<tr>
<td>V</td>
<td>Venlafaxine</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Vital</td>
<td>6</td>
</tr>
<tr>
<td>W</td>
<td>Water</td>
<td>9</td>
</tr>
<tr>
<td>Z</td>
<td>Zyban</td>
<td>10</td>
</tr>
</tbody>
</table>